ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02471391

Recruitment Status : Unknown

Verified June 2015 by Peter MacCallum Cancer Centre, Australia.
Recruitment status was: Recruiting

First Posted : June 15, 2015

Last Update Posted : August 31, 2015

Sponsor:

Information provided by (Responsible Party):

Peter MacCallum Cancer Centre, Australia

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	June 2017
Estimated Study Completion Date :	June 2018

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519.

To Top